{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T15:00:19Z","timestamp":1774450819115,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T00:00:00Z","timestamp":1627430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T00:00:00Z","timestamp":1627430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K21271"],"award-info":[{"award-number":["19K21271"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K15548"],"award-info":[{"award-number":["21K15548"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The risk for radiation necrosis is lower in fractionated stereotactic radiotherapy (SRT) than in conventional radiotherapy, and 13-fraction SRT is our method of choice for the treatment of brain metastases\u2009\u2265\u2009around 2\u00a0cm or patients who are expected to have a good prognosis. As 13-fraction SRT lasts for at least 17\u00a0days, adaptive radiotherapy based on contrast-enhanced mid-treatment magnetic resonance imaging (MRI) is often necessary for patients undergoing 13-fraction SRT. In this study, we retrospectively analyzed interfractional target changes in patients with brain metastases treated with 13-fraction SRT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Our analyses included data from 23 patients and 27 metastatic brain lesions treated with 13-fraction SRT with dynamic conformal arc therapy. The peripheral dose prescribed to the planning target volume (PTV) was 39\u201344.2\u00a0Gy in 13-fractions. The gross tumor volume (GTV) of the initial SRT plan (initial GTV), initial PTV, and modified GTV based on the mid-treatment MRI scan (mid-treatment GTV) were assessed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median initial GTV was 3.8 cm<jats:sup>3<\/jats:sup> and the median time from SRT initiation to the mid-treatment MRI scan was 6\u00a0days. Compared to the initial GTV, the mid-treatment GTV increased by more than 20% in five lesions and decreased by more than 20% in five lesions. Interfractional GTV volume changes of more than 20% were not significantly associated with primary disease or the presence of cystic components\/necrosis. The mid-treatment GTV did not overlap perfectly with the initial PTV in more than half of the lesions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Compared to the initial GTV, the mid-treatment GTV changed by more than 20% in almost one-third of lesions treated with 13-fraction SRT. As SRT usually generates a steep dose gradient as well as increasing the maximum dose of PTV compared to conventional radiotherapy, assessment of the volume and locational target changes and adaptive radiotherapy should be considered as the number of fractions increases.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13014-021-01869-4","type":"journal-article","created":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T09:03:16Z","timestamp":1627462996000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Interfractional target changes in brain metastases during 13-fraction stereotactic radiotherapy"],"prefix":"10.1186","volume":"16","author":[{"given":"Megumi","family":"Uto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Katagiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Takehana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8135-8746","authenticated-orcid":false,"given":"Takashi","family":"Mizowaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,28]]},"reference":[{"issue":"14","key":"1869_CR1","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","volume":"22","author":"JS Barnholtz-Sloan","year":"2004","unstructured":"Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22(14):2865\u201372.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1869_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s11060-015-1888-9","volume":"125","author":"X Zhong","year":"2015","unstructured":"Zhong X, Huang B, Feng J, Yang W, Liu H. Delayed leukoencephalopathy of non-small cell lung cancer patients with brain metastases underwent whole brain radiation therapy. J Neurooncol. 2015;125(1):177\u201381.","journal-title":"J Neurooncol"},{"issue":"4","key":"1869_CR3","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jama.2016.9839","volume":"316","author":"PD Brown","year":"2016","unstructured":"Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, Anderson SK, et al. Effect of radiosurgery alone versus radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA. 2016;316(4):401\u20139.","journal-title":"JAMA"},{"issue":"1","key":"1869_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ijrobp.2005.05.023","volume":"63","author":"MP Mehta","year":"2005","unstructured":"Mehta MP, Tsao MN, Whelan TJ, Morris DE, Hayman JA, Flickinger JC, et al. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys. 2005;63(1):37\u201346.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"Suppl","key":"1869_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3171\/2014.8.GKS141421","volume":"121","author":"M Yamamoto","year":"2014","unstructured":"Yamamoto M, Kawabe T, Sato Y, Higuchi Y, Nariai T, Watanabe S, et al. Stereotactic radiosurgery for patients with multiple brain metastases: a case-matched study comparing treatment results for patients with 2\u20139 versus 10 or more tumors. J Neurosurg. 2014;121(Suppl):16\u201325.","journal-title":"J Neurosurg"},{"key":"1869_CR6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1748-717X-7-36","volume":"7","author":"XS Jiang","year":"2012","unstructured":"Jiang XS, Xiao JP, Zhang Y, Xu YJ, Li XP, Chen XJ, et al. Hypofractionated stereotactic radiotherapy for brain metastases larger than 3 cm. Radiat Oncol. 2012;7:36.","journal-title":"Radiat Oncol"},{"issue":"4","key":"1869_CR7","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.ijrobp.2016.03.013","volume":"95","author":"G Minniti","year":"2016","unstructured":"Minniti G, Scaringi C, Paolini S, Lanzetta G, Romano A, Cicone F, et al. Single-fraction versus multifraction (3 \u00d7 9 Gy) stereotactic radiosurgery for large (>\u00a02 cm) brain metastases: a comparative analysis of local control and risk of radiation-induced brain necrosis. Int J Radiat Oncol Biol Phys. 2016;95(4):1142\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"1869_CR8","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s11060-012-0912-6","volume":"109","author":"K Ogura","year":"2012","unstructured":"Ogura K, Mizowaki T, Ogura M, Sakanaka K, Arakawa Y, Miyamoto S, et al. Outcomes of hypofractionated stereotactic radiotherapy for metastatic brain tumors with high risk factors. J Neurooncol. 2012;109(2):425\u201332.","journal-title":"J Neurooncol"},{"issue":"12","key":"1869_CR9","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1007\/s11604-019-00886-4","volume":"37","author":"K Kubo","year":"2019","unstructured":"Kubo K, Kenjo M, Doi Y, Nakao M, Miura H, Ozawa S, et al. MRI appearance change during stereotactic radiotherapy for large brain metastases and importance of treatment plan modification during treatment period. Jpn J Radiol. 2019;37(12):850\u20139.","journal-title":"Jpn J Radiol"},{"issue":"Suppl 1","key":"1869_CR10","doi-asserted-by":"publisher","first-page":"i76","DOI":"10.1093\/jrr\/rrw015","volume":"57","author":"Y Shibamoto","year":"2016","unstructured":"Shibamoto Y, Miyakawa A, Otsuka S, Iwata H. Radiobiology of hypofractionated stereotactic radiotherapy: what are the optimal fractionation schedules? J Radiat Res. 2016;57(Suppl 1):i76\u201382.","journal-title":"J Radiat Res"},{"issue":"6","key":"1869_CR11","doi-asserted-by":"publisher","first-page":"907","DOI":"10.3171\/jns.2006.104.6.907","volume":"104","author":"MA Vogelbaum","year":"2006","unstructured":"Vogelbaum MA, Angelov L, Lee SY, Li L, Barnett GH, Suh JH. Local control of brain metastases by stereotactic radiosurgery in relation to dose to the tumor margin. J Neurosurg. 2006;104(6):907\u201312.","journal-title":"J Neurosurg"},{"issue":"3","key":"1869_CR12","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3171\/2016.3.JNS153014","volume":"126","author":"AM Mohammadi","year":"2017","unstructured":"Mohammadi AM, Schroeder JL, Angelov L, Chao ST, Murphy ES, Yu JS, et al. Impact of the radiosurgery prescription dose on the local control of small (2 cm or smaller) brain metastases. J Neurosurg. 2017;126(3):735\u201343.","journal-title":"J Neurosurg"},{"issue":"1","key":"1869_CR13","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s11060-015-1881-3","volume":"125","author":"ZA Kohutek","year":"2015","unstructured":"Kohutek ZA, Yamada Y, Chan TA, Brennan CW, Tabar V, Gutin PH, et al. Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases. J Neurooncol. 2015;125(1):149\u201356.","journal-title":"J Neurooncol"},{"issue":"3","key":"1869_CR14","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48(3):452\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"1869_CR15","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13014-018-1083-1","volume":"13","author":"P Lesueur","year":"2018","unstructured":"Lesueur P, Lequesne J, Barraux V, Kao W, Geffrelot J, Grellard JM, et al. Radiosurgery or hypofractionated stereotactic radiotherapy for brain metastases from radioresistant primaries (melanoma and renal cancer). Radiat Oncol. 2018;13(1):138.","journal-title":"Radiat Oncol"},{"key":"1869_CR16","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.radonc.2019.07.011","volume":"142","author":"E Hessen","year":"2019","unstructured":"Hessen E, Nijkamp J, Damen P, Hauptmann M, Jasperse B, Dewit L, et al. Predicting and implications of target volume changes of brain metastases during fractionated stereotactic radiosurgery. Radiother Oncol. 2019;142:175\u20139.","journal-title":"Radiother Oncol"},{"issue":"4","key":"1869_CR17","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.ijrobp.2018.06.021","volume":"102","author":"AL Salkeld","year":"2018","unstructured":"Salkeld AL, Hau EKC, Nahar N, Sykes JR, Wang W, Thwaites DI. Changes in brain metastasis during radiosurgical planning. Int J Radiat Oncol Biol Phys. 2018;102(4):727\u201333.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"1869_CR18","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/1754-9485.12194","volume":"58","author":"K Ohtakara","year":"2014","unstructured":"Ohtakara K, Hoshi H. Target volume geometric change and\/or deviation from the cranium during fractionated stereotactic radiotherapy for brain metastases: potential pitfalls in image guidance based on bony anatomy alignment. J Med Imaging Radiat Oncol. 2014;58(6):729\u201336.","journal-title":"J Med Imaging Radiat Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-021-01869-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-021-01869-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-021-01869-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T09:12:20Z","timestamp":1627463540000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-021-01869-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,28]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1869"],"URL":"https:\/\/doi.org\/10.1186\/s13014-021-01869-4","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,28]]},"assertion":[{"value":"24 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the 1964 Declaration of Helsinki, and all procedures were approved by the institutional ethical review board (R1048). Written informed consent was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"140"}}